Men and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation may qualify for the BROCADE Study. The purpose of this medical research study is to determine the safety and effectiveness of the investigational PARP inhibitor, Veliparib, in combination with chemotherapy in patients with advanced hereditary breast cancer. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive investigational medication or placebo, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available.
How to participate
Key eligibility criteria are:
-Age 18 or over
-Have confirmed breast cancer that has spread beyond the breast and lymph nodes
-Have a BRCA1 or BRCA2 mutation
-Have no more than one prior cancer treatment for metastatic breast cancer
-Healthy enough to be up and out of bed at least half the time
-Are not pregnant or plan to conceive a child (and agree to use adequate contraception)
For more details and to find a participating oncologist, visit the
BROCADE website.
Posts
